• 1. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 2. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 3. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 4. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Steroidal glycosides
• Natural Products and Extracts Plant Extracts Plant based Orthosia guilleminiana

Chemical Profile of Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside (CAS No. 171422-82-5)

Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside, identified by the chemical registration number CAS No. 171422-82-5, is a naturally occurring glycoside that has garnered significant attention in the field of pharmaceutical chemistry and natural product research. This compound, derived from the plant kingdom, exhibits a complex molecular structure characterized by a steroid aglycone core linked to a carbohydrate moiety. The specific glycosylation pattern, featuring an alpha-L-cymaropyranoside residue at the 4''' position, contributes to its unique physicochemical properties and biological activities.

The structural elucidation of Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside has been achieved through a combination of spectroscopic techniques, including nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and high-performance liquid chromatography (HPLC). These analytical methods have revealed the stereochemistry of the glycosidic bond and the arrangement of functional groups within the molecule. Such detailed structural information is crucial for understanding its interactions with biological targets and for designing potential synthetic analogs.

Recent advancements in computational chemistry have enabled the prediction of pharmacokinetic and pharmacodynamic properties of Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside. Molecular docking studies have identified potential binding sites on target proteins, suggesting its utility in modulating various cellular processes. For instance, preliminary in silico analyses have indicated that this compound may interact with enzymes involved in inflammation and oxidative stress pathways, which are implicated in numerous chronic diseases.

Investigations into the biological activities of Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside have demonstrated promising results in preclinical models. Studies have shown that this glycoside exhibits anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Additionally, its ability to scavenge reactive oxygen species has been documented, suggesting a role in antioxidant defense mechanisms.

The anti-cancer potential of Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside has also been explored. Research indicates that this compound can induce apoptosis in certain cancer cell lines by activating caspase-dependent pathways. Furthermore, it has shown promise in inhibiting the proliferation of multidrug-resistant cancer cells, a significant challenge in oncology therapy. These findings underscore the compound's potential as a lead molecule for developing novel anticancer agents.

Another area of interest is the neuroprotective effects of Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside. Preclinical studies have suggested that this glycoside may protect against neurodegenerative diseases by mitigating neuronal damage caused by oxidative stress and inflammation. Its ability to cross the blood-brain barrier has also been noted, which is essential for therapeutic efficacy in central nervous system disorders.

The synthesis of Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside presents both challenges and opportunities. Traditional methods rely on plant extraction, which can be labor-intensive and yield inconsistent results due to variations in natural abundance. However, modern biotechnological approaches, such as microbial fermentation and enzymatic glycosylation, offer more sustainable and scalable production methods. These techniques not only enhance yield but also allow for structural modifications to optimize biological activity.

The pharmacokinetic profile of Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside is another critical aspect that influences its therapeutic potential. Studies have shown that this compound exhibits moderate bioavailability following oral administration, with absorption occurring primarily in the small intestine. Metabolism studies indicate that it undergoes glucuronidation and sulfation before excretion via bile and urine. Understanding these processes is essential for optimizing dosing regimens and minimizing side effects.

Regulatory considerations play a significant role in the development of Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside as a pharmaceutical agent. Compliance with Good Manufacturing Practices (GMP) ensures the quality and consistency of raw materials and final products. Additionally, preclinical safety studies are necessary to assess potential toxicities before human clinical trials can commence. These steps are critical for ensuring patient safety while advancing towards market approval.

The future direction of research on Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside includes exploring its mechanism of action at a molecular level through advanced imaging techniques such as fluorescence microscopy and live-cell imaging. These tools can provide insights into how this compound interacts with cellular components and modulates signaling pathways. Furthermore, interdisciplinary collaborations between chemists, biologists, and clinicians will be essential for translating preclinical findings into effective therapeutic strategies.

In conclusion, Otophylloside B 4'''-O-Alpha-L-Cymaropyranoside (CAS No. 171422-82-5) represents a promising natural product with diverse biological activities ranging from anti-inflammatory to anticancer effects. Its complex structure and unique glycosylation pattern contribute to its therapeutic potential, while ongoing research continues to uncover new mechanisms of action and optimize production methods. As our understanding of this compound evolves, it holds great promise for addressing various human health challenges in the coming decades.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)